CILAG AG

Overview

CILAG AG is an active pharmaceutical ingredient (API) supplier with 4 active FDA Type II Drug Master Files, covering ALCAFTADINE (R89674) DRUG SUBSTANCE; CLADRIBINE DRUG SUBSTANCE; IRON SUCROSE DRUG SUBSTANCE; REMIFENTANIL HCL DRUG SUBSTANCE.

API / Drug Master Files

CILAG AG holds 4 active (24 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• REMIFENTANIL HCL DRUG SUBSTANCEActive2013-09-06
• ALCAFTADINE (R89674) DRUG SUBSTANCEActive2006-12-21
• IRON SUCROSE DRUG SUBSTANCEActive2006-06-26
• CLADRIBINE DRUG SUBSTANCEActive2004-08-16
• FOSPHENYTOIN SODIUM DRUG SUBSTANCE (ACTIVE PHARMACEUTICAL INGREDIENT)Inactive2005-11-14
• SODIUM FERRIC GLUCONATEInactive2004-08-13
• DIVALPROEX SODIUMInactive2002-11-05
• DOXAZOSIN MESYLATEInactive1999-06-03
• TERAZOSIN HYDROCHLORIDE MONOHYDRATEInactive1997-09-08
• CLADRIBINEInactive1996-11-21
• FLUOXETINE HYDROCHORIDEInactive1996-11-15
• BUPROPION HYDROCHLORIDEInactive1996-08-12
• OXAPROZINInactive1996-02-28
• KETOROLAC TROMETHAMINEInactive1996-01-04
• RETINAMIDIC ACIDInactive1995-07-13

Showing 15 of 24 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to CILAG AG in our records. PharmaTek screens the full directory against live FDA enforcement data.